Effects of genetic variation in the P2RX7 gene on pharmacodynamics of a P2X 7 receptor antagonist: A prospective genotyping approach

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 376-380

  McHugh, Simon M ^a   Roman, Shilina ^a   Davis, Bill ^a   Koch, Annelize ^a   Pickett, Alison M ^a   Richardson, Jill C ^a   Miller, Sam R ^a   Wetten, Sally ^a   Cox, Charles J ^a   Karpe, Fredrik ^b   Todd, John A ^c   Bullmore, Edward T ^a,d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bioresource; GSK1370319A; P2RX7 gene; P2X 7 antagonist; Single nucleotide polymorphism

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE; CYSTEINE; GLUTAMINE; GLYCINE; GSK 1370319 A; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2X7 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; THREONINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG INHIBITION; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; IC 50; LOSS OF FUNCTION MUTATION; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOSINE TRIPHOSPHATE; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRROLIDINES; RECEPTORS, PURINERGIC P2X7;

EID: 84863749568     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04200.x     Document Type: Article

References (17)

1. Craigen JL, Mackus JM, Engleberts P, Miller SR, Speller S, Chamberlain L, Davis BG, McHugh SM, Bullmore ET, Cox CJ, Wetten S, Perdock G, Bakker JM, van de Winkel JGJ, Parren PWHI. Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC. Blood 2009; 114: 1725 (ASH Annual Meeting Abstracts).
2. Dendrou CA, Plagnol V, Fung E, Yang JHM, Downes K, Cooper JD, Nutland S, Coleman G, Himsworth M, Hardy M, Burren O, Healy B, Walker NM, Koch K, Ouwehand WH, Bradley JR, Wareham NJ, Todd JA, Wicker LS. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009; 41: 1011-5.
3. Soranzo N, Spector TD, Mangino M, Kühnel B, Rendon A, Teumer A, Willenborg C, Wright B, Chen L, Li M, Salo P, Voight BF, Burns P, Laskowski RA, Xue Y, Menzel S, Altshuler D, Bradley JR, Bumpstead S, Burnett MS, Devaney J, Döring A, Elosua R, Epstein SE, Erber W, Falchi M, Garner SF, Ghori MJR, Goodall AH, Gwilliam R, Hakonarson HH, Hall AS, Hammond N, Hengstenberg C, Illig T, König IR, Knouff CW, McPherson R, Melander O, Mooser V, Nauck M, Nieminen MS, O'Donnell CJ, Peltonen L, Potter SC, Prokisch H, Rader DJ, Rice CM, Roberts R, Salomaa V, Sambrook J, Schreiber S, Schunkert H, Schwartz SM, Serbanovic-Canic J, Sinisalo J, Siscovick DS, Stark K, Surakka I, Stephens J, Thompson JR, Völker U, Völzke H, Watkins NA, Wells GA, Wichmann HE, Van Heel DA, Tyler-Smith C, Thein SL, Kathiresan S, Perola M, Reilly MP, Stewart AFR, Erdmann J, Samani NJ, Meisinger C, Greinacher A, Deloukas P, Ouwehand WH, Gieger C. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009; 41: 1182-90.
4. Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis L, Fielding BA, Karpe F. The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia 2006; 49: 158-68.
5. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 2009; 158 (SUPPL. 1): S1.
6. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013-67.
7. Pelegrin P, Surprenant A. The P2X7 receptor - Pannexin connection to dye uptake and IL-1b release. Purinergic Signal 2009; 5: 129-37.
8. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: A key player in IL-1 processing and release. J Immunol 2006; 176: 3877-83.
9. Jha S, Srivastava SY, Brickey WJ, Iocca H, Toews A, Morrison JP, Chen VS, Gris D, Matsushima GK, Ting JP-Y. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 2010; 30: 15811-20.
10. Carroll WA, Donnelly-Roberts D, Jarvis MF. Selective P2X7 receptor antagonists for chronic inflammation and pain. Purinergic Signal 2009; 5: 63-73.
11. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A. The permeabilizing ATP receptor, P2X7 Cloning and expression of a human cDNA. J Biol Chem 1997; 272: 5482-6.
12. Fuller SJ, Stokes L, Skarratt KK, Gu BJ, Wiley JS. Genetics of the P2X7 receptor and human disease. Purinergic Signal 2009; 5: 257-62.
13. Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, Wiley JS. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1β secretion. FASEB J 2010; 24: 2916-27.
14. Gu BJ, Zhang W, Worthington RA, Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, Petrou S, Barden JA, Wiley JS. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-42.
15. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006; 58: 58-86.
16. Evans RJ. Structural interpretation of P2X receptor mutagenesis studies on drug action. Br J Pharmacol 2010; 161: 961-71.
17. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008; 40: 187-224.